5-HTP’s story runs from a West African seed to 1970s pharmacology labs to today’s supplement shelves. Understanding that path helps explain why the research base looks the way it does.
This article is for educational purposes and is not medical advice. 5-HTP affects serotonin, the same system targeted by antidepressants, triptans, and several other prescription drugs. Talk to a doctor or pharmacist before starting 5-HTP, especially if you take any prescription medication, are pregnant or breastfeeding, or have an existing health condition. This post may contain affiliate links; we may earn a commission at no extra cost to you.
Griffonia simplicifolia: Traditional Use
Griffonia simplicifolia is a woody shrub native to West Africa, and its seeds are unusually rich in 5-HTP, at 6 to 20% of their wet weight. Its recorded traditional uses had little to do with mood: insecticides, fodder, dyes and chewing sticks among them. The seeds became an export crop instead. By the late 1980s Ghana was shipping 75 to 80 tonnes a year to Europe, and wild West African plants are still the only commercial source[1].
Scientific Isolation and Early Research
5-HTP was studied in labs long before it reached consumer supplements. Many of the early human trials ran in the 1970s and 1980s, largely in depression, at a time when the serotonin hypothesis of depression was gaining traction. One 1977 double-blind trial, for example, found no difference in efficacy between 5-HTP and the antidepressant imipramine[2].
From Pharmaceutical Interest to Supplement Market
5-HTP leads two regulatory lives. Under its drug name, oxitriptan, the WHO’s drug classification lists it among antidepressants[3], while in the United States it is sold as a dietary supplement. Either way, its trial base stayed small. When a 2002 Cochrane review looked at 108 trials of 5-HTP and tryptophan for depression, only two, with 64 patients in total, were rigorous enough to include, and the authors called for more research on efficacy and safety before widespread use[4].
The Tryptophan Recall and Its Ripple Effect
In 1989, an outbreak of eosinophilia-myalgia syndrome (EMS) in the United States was traced to L-tryptophan supplements made by a single company using a fermentation process[5], and tryptophan supplements were recalled. 5-HTP is made differently, by extraction from Griffonia seed, but it has its own contamination history: a family of contaminants called peak X was found in 5-HTP linked to EMS cases and in all eight commercial samples tested in 1999[6]. A 2003 study identified one of them as a possible neurotoxin[7], which is why third-party purity testing matters for 5-HTP specifically.
Frequently Asked Questions
Is 5-HTP the same thing as the tryptophan involved in the 1989 recall?
No, they are related but distinct molecules. The 1989 EMS outbreak was tied to a contaminated tryptophan manufacturing process at one specific supplier, not to tryptophan or 5-HTP as molecules. It’s still a reason to buy from brands that third-party test for purity.
Why did 5-HTP research decline after the 1980s-90s?
We can’t point to a documented single cause. What is documented is the result: a 2002 Cochrane review found only two of 108 trials rigorous enough to include, which leaves much of the foundational research small and decades old.
Is Griffonia simplicifolia sustainably sourced?
Sourcing varies by supplier. The seeds are wild-harvested in West Africa, and a 2021 review of the trade raised concerns about whether that harvest can be sustained, including habitat loss and destructive harvesting methods.
References
- From forest to pharmacy: Should we be depressed about a sustainable Griffonia simplicifolia (Fabaceae) seed supply chain?. Journal of Ethnopharmacology, 2021
- The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study. Archiv fur Psychiatrie und Nervenkrankheiten, 1977
- ATC/DDD Index: N06AX01 oxitriptan (N06AX Other antidepressants). WHO Collaborating Centre for Drug Statistics Methodology
- Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews, 2002
- An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. New England Journal of Medicine, 1990
- Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Advances in Experimental Medicine and Biology, 1999
- Structural characterization of a case-implicated contaminant, “Peak X,” in commercial preparations of 5-hydroxytryptophan. Journal of Rheumatology, 2003
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.

